Publications by authors named "Amanda Maggiotto"
Article Synopsis
- Breast cancer during pregnancy, known as pregnancy-associated breast cancer (PABC), is uncommon but is one of the most frequent cancers found in pregnant women.
- PABC involves unique risk factors and treatment considerations, requiring a tailored management approach that prioritizes the health of both the mother and fetus.
- A comprehensive strategy that includes multidisciplinary collaboration and careful timing of treatments is essential, with post-delivery support addressing contraception, breastfeeding, and fertility issues also being crucial.
Background: Time to treatment initiation (TTI) is a quality metric in cancer care. The purpose of this study is to determine the accuracy of TTI data from a single cancer center registry that reports to the National Cancer Database (NCDB) for sarcoma diagnoses.
Methods: A retrospective analysis of a single Commission on Cancer (CoC)-accredited cancer center's tumor registry between 2006 and 2016 identified 402 patients who underwent treatment of a musculoskeletal soft tissue sarcoma and had TTI data available.
This study aimed to identify the rate and impact of vancomycin-resistant enterococcal (VRE) bacteremia in patients with acute myeloid leukemia (AML) receiving induction chemotherapy (IC). Thirty-seven (10.6%) of 350 patients had VRE bacteremia during IC, with increasing rates of VRE bacteremia over the course of the study period.
View Article and Find Full Text PDFMantle cell lymphoma (MCL) is a unique, recently recognized entity with a variable clinical course [1]. Its historical grouping as an indolent lymphoma belies its common behavior, which is generally aggressive and incurable, with a median survival of about 5 years with modern therapy [2]. In an effort to improve outcomes in MCL, intensified therapies, including the rituximab plus HyperCVAD regimen [3] and incorporation of hematopoetic progenitor cell transplantation (HPCT) [4-6], have been used.
View Article and Find Full Text PDF